(Q36385285)

13 August 2017

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients (English)

1 reference

13 August 2017

1 reference

1 reference

E Lou

6

0 references

Henry Seth Friedman

16

object named as

H S Friedman

1 reference

13 August 2017

15

D D Bigner

1 reference

13 August 2017

4

A Desjardins

1 reference

13 August 2017

D A Reardon

1

1 reference

13 August 2017

J E Herndon

2

1 reference

13 August 2017

K B Peters

3

1 reference

13 August 2017

A Coan

5

1 reference

13 August 2017

A L Sumrall

7

1 reference

13 August 2017

S Turner

8

1 reference

13 August 2017

E S Lipp

9

1 reference

13 August 2017

S Sathornsumetee

10

1 reference

13 August 2017

J N Rich

11

1 reference

13 August 2017

J H Sampson

12

1 reference

13 August 2017

A H Friedman

13

1 reference

13 August 2017

S T Boulton

14

1 reference

13 August 2017

J J Vredenburgh

17

1 reference

13 August 2017

language of work or name

English

0 references

publication date

4 October 2012

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

107

1 reference

13 August 2017

9

1 reference

13 August 2017

1481-1487

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.415

13 August 2017

0 references

cites work

Bevacizumab and daily temozolomide for recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493761

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.415

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23037712

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.415

1 reference

13 August 2017

1 reference

13 August 2017

1 reference